Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Treating Late-Stage Prostate Cancer

This article was originally published in Start Up

Executive Summary

Prostate cancer was the cause of 28,666 deaths in 2008, or 10% of cancer deaths in the US, and roughly 186,000 men are diagnosed with the disease each year. Docetaxel, a chemotherapeutic agent, is the only FDA-approved drug to treat late-stage prostate cancer, leaving a significant need that many biotechs and pharmaceutical firms are trying to meet. Results are starting to roll in from several key clinical trials of late-stage prostate cancer therapies. Start-ups embarking on drug development may face significant competition.
Advertisement

Related Content

Genentech Exec Heads East To Take The Reins Of Cancer-Focused Start-up Agios
Med Discovery SA
Colby Pharmaceutical Co.
Start-Up Previews (03/2009)
Bellicum Pharmaceuticals Inc.
AndroBioSys Inc.
Medivation’s Prostate Cancer Drug Strong In Phase I/II
Medivation’s Prostate Cancer Drug Strong In Phase I/II
The Provenge Precedent
The Provenge Precedent

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091764

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel